AstraZeneca, Schering AG Partner On Developmental SERD Breast Cancer Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Collaboration will build on AstraZeneca’s expertise with Faslodex.
You may also be interested in...
Bayer Schering Licenses Oncology Candidate To Molecular Insight
The Cambridge, Mass. biotech will develop the compound as a radiotherapeutic for malignant melanoma.
Bayer Schering Licenses Oncology Candidate To Molecular Insight
The Cambridge, Mass. biotech will develop the compound as a radiotherapeutic for malignant melanoma.
Schering Integration On Track, Bayer CEO Says
Schering AG stockholders to vote Sept. 13 on a domination and profit and loss transfer agreement with Bayer subsidiary Dritte BV.